Wave claimed GSK is handing back rights to the frontrunning program not because of questions about its potential, but because ...

After GSK’s return of Wave Life Sciences’ WVE-006 as well as the mid-stage failure of Korro Bio’s candidate, the alpha-1 ...

Wave Life Sciences has the fate of its lead RNA editing candidate back in its own hands. | Wave Life Sciences has the fate of its lead RNA editing candidate back in its own hands. GSK has decided not ...

Korro Bio (NASDAQ:KRRO) used its Analyst Day to outline the rationale and development plans for KRRO-121, an RNA-editing therapeutic candidate the company believes could provide a new approach to ...

While GSK did not provide a specific reason for returning Wave Life Sciences’ WVE-006, the decision comes after the asset in September 2025 came below analyst expectations in a Phase Ib/IIa AATD study ...

As part of its ongoing governance practices, the Board regularly reviews its composition to ensure it maintains an ...

Researchers reprogrammed bacterial bridge recombinases to edit large genomic regions in mammalian cells, revealing a ...

Wave Life Sciences (WVE) was not the only developer of RNA editing therapies to show significant stock gains from its historic proof-of-mechanism for its RNA editing platform, shown recently in the ...

Parkinson's disease (PD) is a neurodegenerative disorder in which the α-synuclein protein abnormally aggregates within brain cells, causing neuronal damage. Through international collaboration, ...

Over the past few years, the excitement over genome editing has moved well beyond the original CRISPR-Cas system described a decade ago, into areas such as the discovery of new Cas systems, CRISPR ...